United States and Japan - Proton Therapy Market, Patients & Forecast

Researchmoz presents this most up-to-date research on"United States and Japan - Proton Therapy Market, Patients & Forecast". The report focuses primarily on quantitative market metrics in order to characterize the growth and evolution of the Remote Patient Monitoring Market.

Browse Full Report With TOC At : http://www.researchmoz.us/united-states-and-japan-proton-therapy-market-patients-and-forecast-report.html

Proton therapy has become a subject of considerable interest in the radiation oncology community and it is expected that there will be a substantial growth in proton treatment facilities during the next decade. Proton therapy, one of the most intriguing developments in cancer treatment, carries a price tag as intimidating as its size. At a cost of US$ 125 Million, and sometimes much more, today’s centers usually fill a city block. Building and equipping a facility carries financial and logistical challenges that dwarf nearly any other capital project. Even health care systems with deep pockets might not have sufficient land available, particularly in urban areas.

Market Research Related Reports :

Epilepsy Therapeutics in Asia Pacific Markets to 2019 http://www.researchmoz.us/epilepsy-therapeutics-in-asia-pacific-markets-to-2019-treatment-options-enhanced-as-novel-next-generation-aeds-show-improved-safety-and-tolerability-report.html

Research, the leading business intelligence provider, has released its latest research: ‘Epilepsy Therapeutics to 2019 in Asia-Pacific Market’, which provides in-depth analysis of epilepsy market within the Asia-Pacific (APAC) market covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.  

The value of the epilepsy market in the APAC region amounted to an estimated $1.1 billion in 2012 and is expected to register a Compound Annual Growth Rate (CAGR) of 4.7% to reach $1.5 billion by 2019. The key drivers for growth in the APAC market include: high prevalence in China and India, increased market penetration due to improved market access in China and the expected approvals of drugs with novel mechanisms of action which could expand the therapeutic scope.

Investigation Report on China Quetiapine Market, 2009 - 2018 http://www.researchmoz.us/investigation-report-on-china-quetiapine-market-2009-2018-report.html

Schizophrenia is a common mental disorder. As a chronic disease, schizophrenia can lead to recurrent or persistent symptoms in most patients' whole life. As Chinese economy and society develops, life and work here has become increasingly stressful. As a result, recurrence rate of schizophrenia has also increased. Statistics shows that the number of schizophrene in China has exceeded 10 million by the end of 2013, and it is still rising year after year. Quetiapine is originally developed by Astra Zeneca and has curative effect on various schizophrenic symptoms. It was firstly approved to the U.K. market in July 1997 and to the U.S. market on September 26, 1997 by FDA with the trade name "Seroquel". Patent of this product expired on March 26, 2012.

For More Related Reports On Therapeutic Area Visit At : http://www.researchmoz.us/therapeutic-area-market-reports-37.html

For More Information Kindly Contact:
Email: sales@researchmoz.us
Web Site: http://www.researchmoz.us/
Blog: http://globalandchinamarket.blogspot.com
word press : http://marketresearchtopix.wordpress.com